EUVIMEDSkopri EUVIMED
Klinische Studie (Phase II)Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen access · CC BY-NC 4.0

Long‐term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow‐up in the SELECTION open‐label long‐term extension study

Brian G Feagan, Katsuyoshi Matsuoka, Gerhard Rogler, David Laharie iD, Séverine Vermeire, Silvio Danese iD, Edward V Loftus iD, Ian Beales iD, Stefan Schreiber iD, Hyo Jong Kim, Margaux Faes, Angela de Haas and 3 more

Alimentary Pharmacology & Therapeutics · 2024-09 · 60 (5) · 563-584

DOI: 10.1111/apt.18158 ↗

At a glance

Klinische Studie (Phase II) in Alimentary Pharmacology & Therapeutics, published online on 2024-07-31. Written by Brian G Feagan and 14 co-authors. Institution: Alimentiv Inc., London, Ontario, Canada. Major MEDLINE topics: Colitis, Ulcerative, Quality of Life, Severity of Illness Index. Cited 18 times so far (Crossref); 23 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Gilead Sciences, Inc, Galapagos NV, Gilead Sciences.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Filgotinib, an oral, once‐daily, Janus kinase 1 preferential inhibitor, is an approved treatment for moderately to severely active ulcerative colitis.

Aims

The aim of this study is to assess the safety and efficacy of continued filgotinib therapy over ~4 years in the long‐term extension of the phase 2b/3 SELECTION trial (SELECTIONLTE; NCT02914535).

Methods

In this interim analysis of SELECTIONLTE, SELECTION completers (week 10 responders to filgotinib who completed the maintenance study) continued their assigned treatment (double‐blind filgotinib 200 mg [FIL200] or filgotinib 100 mg) and SELECTION week 10 non‐responders received open‐label FIL200. We assessed safety by adverse events (AEs), and efficacy by partial Mayo Clinic Score (pMCS), inflammatory biomarkers and health‐related quality of life (HRQoL). We compared safety and efficacy between achievers and non‐achievers of a multi‐component endpoint, comprehensive disease control (CDC), comprising symptomatic, endoscopic, inflammatory biomarker and HRQoL improvements.

Results

Data for completers ( n = 250) and non‐responders ( n = 372) were reported for ≤202 weeks. AE occurrences were low and consistent with previous analyses. The as‐observed proportion of FIL200‐treated patients in pMCS, biomarker and HRQoL remission during SELECTIONLTE remained high among completers (week 144: 80.0%, 86.4% and 86.0%, respectively) and increased among non‐responders (week 192: 62.1%, 76.7% and 59.3%, respectively). Significantly higher proportions of CDC achievers at SELECTION week 58 achieved pMCS, IBDQ and corticosteroid‐free pMCS remission than non‐achievers, up to LTE week 96.

Conclusions

Filgotinib induced and maintained symptomatic remission and improved HRQoL over 4 years. Safety results showed a proven long‐term benefit–risk profile. FIL200‐treated CDC achievers had better long‐term outcomes than non‐achievers.

Subjects

MeSH terms (MEDLINE)

Colitis, UlcerativeQuality of LifeSeverity of Illness IndexHumansMaleFemaleAdultMiddle AgedDouble-Blind MethodTreatment OutcomeFollow-Up StudiesTriazolesPyridinesYoung Adult

Substances

GLPG0634TriazolesPyridines

Authors and institutions

  • Alimentiv Inc., London, Ontario, Canada.
  • Western University, London, Ontario, Canada.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Toho University Sakura Medical Center, Chiba, Japan.
  • Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Gastroenterology Department, Hospital Center University de Bordeaux, Magellan Medico-Surgical Center, Haut-Lévêque Hospital, University of Bordeaux, INSERM, Bordeaux, France.
  • Department of Gastroenterology and Hepatology, UZ Leuven, Leuven, Belgium.

ORCID profiles: David Laharie, Silvio Danese, Edward V Loftus, Ian Beales, Stefan Schreiber, Laurent Peyrin-Biroulet

Funding

  • Gilead Sciences, Inc
  • Galapagos NV
  • Gilead Sciences
  • Galápagos

Cite

APA

Feagan, B. G., Matsuoka, K., Rogler, G., Laharie, D., Vermeire, S., Danese, S., Loftus, E. V., Beales, I., Schreiber, S., Kim, H. J., Faes, M., de Haas, A., Masior, T., Rudolph, C., & Peyrin-Biroulet, L. (2024). Long‐term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow‐up in the SELECTION open‐label long‐term extension study. Alimentary Pharmacology & Therapeutics, 60(5), 563-584. https://doi.org/10.1111/apt.18158

Vancouver

Feagan BG, Matsuoka K, Rogler G, Laharie D, Vermeire S, Danese S, et al. Long‐term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow‐up in the SELECTION open‐label long‐term extension study. Alimentary Pharmacology & Therapeutics. 2024;60(5):563-584. doi:10.1111/apt.18158

BibTeX
@article{Feagan2024,
  author = {Feagan, Brian G and Matsuoka, Katsuyoshi and Rogler, Gerhard and Laharie, David and Vermeire, Séverine and Danese, Silvio and Loftus, Edward V and Beales, Ian and Schreiber, Stefan and Kim, Hyo Jong and Faes, Margaux and de Haas, Angela and Masior, Tomasz and Rudolph, Christine and Peyrin-Biroulet, Laurent},
  title = {Long‐term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow‐up in the SELECTION open‐label long‐term extension study},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  volume = {60},
  number = {5},
  pages = {563--584},
  doi = {10.1111/apt.18158}
}
Start for free →